Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Key Points

• Gilead CFO Andrew Dickinson sold 3,000 shares at an average price of $145.29, totaling approximately $435,870. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, leaving him with 164,096 shares.
• Gilead reported quarterly revenue of $7.80 billion, ahead of the $7.40 billion consensus estimate, while revenue increased 10.6% year over year. The company also declared a quarterly dividend of $0.82 per share, yielding approximately 2.2% annually.
• Wall Street maintains a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $158.78. Gilead shares recently traded at $147.68, below the consensus target but near the upper portion of their 12-month range.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total transaction of $435,870.00. Following the completion of the sale, the chief financial officer owned 164,096 shares of the company's stock, valued at $23,841,507.84. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Price Performance

GILD traded up $1.38 on Wednesday, reaching $147.68. 5,078,675 shares of the company's stock were exchanged, compared to its average volume of 6,907,595. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The stock has a market cap of $183.12 billion, a PE ratio of -55.31 and a beta of 0.33. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock's fifty day moving average price is $139.02 and its 200-day moving average price is $136.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. Gilead Sciences's quarterly revenue was up 10.6% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently -122.85%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Morgan Stanley lowered their price objective on Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a research note on Monday, July 27th. Zacks Research upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, August 31st. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Daiwa Securities Group dropped their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday, May 19th. Finally, Maxim Group upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $158.78.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Anchor Investment Management LLC raised its holdings in Gilead Sciences by 843.7% in the 2nd quarter. Anchor Investment Management LLC now owns 2,831 shares of the biopharmaceutical company's stock valued at $358,000 after buying an additional 2,531 shares during the period. Bullseye Investment Management LLC purchased a new position in Gilead Sciences during the second quarter worth about $2,085,000. Talon Private Wealth LLC purchased a new position in Gilead Sciences during the second quarter worth about $212,000. Core Capital Management & Research inc. acquired a new stake in shares of Gilead Sciences during the second quarter valued at about $40,000. Finally, Sequoia Financial Advisors LLC increased its position in shares of Gilead Sciences by 16.9% during the second quarter. Sequoia Financial Advisors LLC now owns 58,662 shares of the biopharmaceutical company's stock valued at $7,411,000 after acquiring an additional 8,484 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead expanded six royalty-free voluntary licensing agreements to include the investigational once-yearly formulation of lenacapavir for HIV pre-exposure prophylaxis. The agreements cover 120 primarily low- and lower-middle-income countries and support manufacturing readiness, technology transfer and future supply planning. The move strengthens Gilead’s global HIV-prevention strategy and could broaden the treatment’s long-term reach if approved. Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
• Positive Sentiment: Gilead and the Pan American Health Organization agreed to expand access to twice-yearly lenacapavir across Latin America and the Caribbean, adding 14 countries to the company’s access efforts. Broader distribution may support future commercial adoption and reinforces lenacapavir’s growth potential in HIV prevention. Gilead and PAHO Announce Lenacapavir Partnership
• Neutral Sentiment: The licensing and PAHO announcements are strategically favorable but are not expected to produce an immediate material revenue contribution, since access agreements emphasize affordability and the once-yearly product remains subject to clinical and regulatory approval.
• Negative Sentiment: Gilead’s $0.82-per-share dividend went ex-dividend on September 15. The resulting mechanical share-price adjustment can create short-term pressure, though the payout remains supportive for income-focused investors. Gilead Sciences Dividend Analysis

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.